AfroCentric Investment Corporation Limited Stocks

ZAC 75Last Updated 28.04.2026

Issuer Rating

3/7
Performance

Favourable

Risk

High

Recommendation

Sell

Market Cap

ZAC 391982.3448

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
ZAC 75
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

AfroCentric Investment Corporation Limited, an investment holding company, provides health administration and health risk management solutions to the healthcare sector. The company operates through Healthcare SA, Healthcare Retail, Healthcare Africa, and Information Technology segments. It offers documentation based care equipment and administration services to 12 musculoskeletal treatment centers; and engages in the retail and wholesale of pharmaceutical products under the Pharmacy Direct, MMed, Scriptpharm Risk Management, Curasana Wholesaler, and Activo Health names. The company also provides HIV and other healthcare management solutions. It operates in South Africa, Botswana, Mauritius, Namibia, Eswatini, and Zimbabwe. AfroCentric Investment Corporation Limited was incorporated in 2008 and is based in Roodepoort, South Africa.

Company Valuation

Greatly undervalued
7/7

From both historical and forecast perspectives, the stock is considerably underpriced compared to similar stocks. In particular, the stock is 'cheap' on EV/EBITDA, underv

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks